Why Didn't Pfizer and BioNTech Stocks Soar After Their COVID Vaccine Achieved 100% Efficacy in Kids?

We've known for a while that the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) was highly effective in individuals ages 16 and up. The two partners recently announced an impressive 100% efficacy for the vaccine in children between the ages of 12 and 15. In this Motley Fool Live video recorded on March 31, Motley Fool contributors Keith Speights and Brian Orelli discuss why neither of these stocks soared after the news about this great efficacy in kids.